Genes2me (P) Limited
Genes2Me is an Indian molecular diagnostics company founded in 2016 that manufactures CE-IVD marked IVD kits, instruments, and NGS clinical assays, and operates a genetic testing laboratory and direct-to-consumer personalized genetics brands, serving clinical laboratories, hospitals, and consumers across 55+ countries.
- Company typePrivate
- Founded2016
- HeadquartersGurugram, India
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Genes2me (P) Limited does
Genes2Me (P) Limited is an Indian molecular diagnostics company founded in 2016 and headquartered in Gurgaon, with a 150,000 sq. ft. automated manufacturing facility in Manesar, Haryana. The company develops and manufactures in vitro diagnostic (IVD) kits, instruments, and reagents spanning four core product categories: NGS Clinical Assays (oncology panels, liquid biopsy, whole exome sequencing, NIPT, pharmacogenomics, infectious disease, HLA typing), Point-of-Care solutions (OnePCR fully automated extraction-plus-RT-PCR system, Rapi-Q rapid testing platform), open IVD RT-PCR systems (RAPiCycler 96 and compatible kits), and nucleic acid extraction solutions (Rapi-X96/X16/X CF/X LB instruments plus MagNXT and SpiNXT kits). Underlying technology combines RT-PCR, next-generation sequencing, magnetic-bead and spin-column extraction, and a cloud-based bioinformatics interpreter (CliSeq Interpreter). The portfolio carries CE-IVD marking and is manufactured under ISO 13485:2016 and ISO 9001:2015 quality systems.
The company operates a hybrid business model with three revenue streams: (i) IVD kit and instrument hardware sales through a global network of 80+ distributors across 40+ countries and presence in 55+ countries; (ii) genetic testing services through a laboratory offering more than 1,600 tests spanning biochemistry, clinical pathology, immunology, microbiology, oncology, pharmacogenomics, and prenatal screening; and (iii) NGS clinical assay panel licensing. In India, Genes2Me also runs direct sales with home sample collection and a 1800-number booking line, plus a direct-to-consumer channel for personalized genetics brands (Genes2Fit, Genes2Health, Med4Me, HealthyMe). The company achieved significant COVID-era scale, reportedly producing 70 million+ test kits and supplying 1 in 5 RT-PCR tests in India, and is led by Founder & CEO Neeraj Gupta (recognized by Forbes as 'Insightful Icon' in 2021), Chairman SK Gupta (ex-Becton Dickinson operations leadership), and COO Ritu Gupta. Genes2Me is privately held and bootstrapped, with no external funding rounds disclosed.
Genes2me (P) Limited firmographics
Firmographics- Name
- Genes2me (P) Limited
- Legal name
- Genes2Me Private Limited
- Website
- https://genes2me.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Genes2Me is an Indian molecular diagnostics company founded in 2016 that manufactures CE-IVD marked IVD kits, instruments, and NGS clinical assays, and operates a genetic testing laboratory and direct-to-consumer personalized genetics brands, serving clinical laboratories, hospitals, and consumers across 55+ countries.
- Ownership category
- akta.pro rank
Genes2me (P) Limited industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Genes2me (P) Limited is headquartered
LocationHeadquarters
- HQ city
- Gurugram
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Genes2me (P) Limited business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- IVD Kits and Instruments Sales: Manufacturing and selling of in-vitro diagnostic kits including RT-PCR testing kits, POCT solutions, and instruments (OnePCR, Rapi-Q, RAPiCycler 96, Rapi-X series). Products are CE-IVD marked and sold globally through distributor network.
- Genetic Testing Services: Laboratory testing services in biochemistry, clinical pathology, immunology, microbiology, pharmacogenomics, cardiology, neurology, oncology, genetic conditions, prenatal screening, HLA typing, and inherited cancer testing.
- NGS Clinical Assays: Sale of Next Generation Sequencing clinical assay panels for oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | BRCA1 and BRCA2 Gene Testing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Genes2me (P) Limited product offering
Product offeringCore offering
Genes2Me develops, manufactures, and sells in vitro diagnostic (IVD) solutions including real-time PCR testing kits, NGS clinical assay panels, point-of-care molecular testing instruments, and automated nucleic acid extraction systems. The company also operates a genetic testing laboratory service offering personalized diagnostics for mother & child care, oncology, infectious diseases, rare diseases, and direct-to-consumer genetic profiling such as Genes2Fit, Genes2Health, Med4Me, and HealthyMe.
Product overview
Genes2Me (P) Limited is an Indian molecular diagnostics company established in 2016 that develops and manufactures a comprehensive portfolio of in vitro diagnostic (IVD) solutions. The company's offerings span four core product categories: NGS Clinical Assays (high-performance next-generation sequencing panels for oncology, liquid biopsy, whole exome sequencing, NIPT, pharmacogenomics, and infectious diseases), Point-of-Care Solutions (including the proprietary OnePCR fully automated detection system and Rapi-Q rapid testing platform), IVD RT-PCR Testing Kits (open real-time PCR platforms including RAPiCycler 96 for high-throughput testing), and Nucleic Acid Extraction Solutions (automated instruments like Rapi-X96/X16/X CF/X LB and extraction kits including SpiNXT and MagNXT). The portfolio is complemented by proprietary bioinformatics platforms such as CliSeq Interpreter for genomic data analysis. A vast majority of Genes2Me products are CE-IVD marked, with the company operating a state-of-the-art 150,000 sq. ft. manufacturing facility in Manesar, India, and distributing across 55+ countries globally.
Differentiator
Problem solved
Functional benefit
Brands
- OnePCR: Fully automated sample-to-result PCR detection system integrating automated nucleic acid extraction and RT-PCR into a single workflow, enabling detection of up to 20 targets from a single sample.
- Rapi-Q
- EZY AutoPrep
- CliSeq Interpreter
- Genes2Fit
- Genes2Health
- Med4Me
- HealthyMe
Products and services
- NGS Clinical Assays High-performance next-generation sequencing panels designed for accurate, reliable, and clinically actionable genomic insights, covering oncology, liquid biopsy, whole exome sequencing, NIPT, pharmacogenomics, and infectious disease testing. Sold to clinical laboratories and healthcare providers globally.
- Point-of-Care Solutions Rapid, user-friendly point-of-care systems enabling timely and reliable molecular testing at or near the patient, including automated instruments and POCT assays. Targeted at clinical laboratories, hospitals, and near-patient settings.
- IVD RT-PCR Testing Kits Flexible and scalable real-time PCR testing kits and open platforms offering compatibility with a wide range of assays and laboratory workflows for clinical diagnostics across oncology, respiratory, reproductive, infectious, vector-borne, bloodborne, and genetic disorders.
- Nucleic Acid Extraction Solutions Efficient and dependable nucleic acid extraction systems and kits (spin-column and magnetic bead-based) designed to deliver high-quality samples for downstream molecular analysis, including automated instruments and manual extraction kits.
- OnePCR Fully automated nucleic acid detection system that integrates automated nucleic acid extraction and RT-PCR into a single seamless workflow, enabling detection of up to 20 targets from a single sample. Sold to clinical laboratories as a CE-IVD marked instrument.
- RAPiCycler 96 Open real-time PCR system designed for high-throughput molecular testing, processing 96 samples with flexible assay compatibility. Sold as a CE-IVD marked instrument to clinical laboratories.
- Rapi-Q Rapid and compact point-of-care RT-PCR testing platform engineered for fast, sensitive, and multiplex testing with larger throughput. Targeted at near-patient and decentralized testing environments.
- EZY AutoPrep-48 Automated NGS library preparation workstation designed to optimize library preparation through enhanced accuracy, reproducibility, and scalability for 48 samples. Compatible with Illumina workflows.
- EZY AutoPrep-24 Automated NGS library preparation workstation for processing 24 samples with enhanced accuracy, reproducibility, and scalability. Targeted at smaller-throughput clinical laboratories.
- Rapi-X96 High-throughput fully automated nucleic acid extraction system designed for large-scale sample processing in clinical and reference laboratories.
- Rapi-X16 Compact nucleic acid extraction system ideal for point-of-care testing environments with smaller throughput needs.
- Rapi-X CF Cell-free nucleic acid extraction automation system designed for NIPT applications and cell-free DNA isolation from maternal blood samples.
- Rapi-X LB Nucleic acid extraction automation system designed for processing liquid biopsy samples for oncology applications.
- CliSeq Interpreter Cloud-based bioinformatics platform for accurate, flexible, and intuitive interpretation of complex genomic data, enabling laboratories to generate high-confidence clinical insights from NGS results.
- MagRNA-II Viral RNA Extraction Kit In-vitro diagnostic solution for rapid and efficient isolation of viral RNA from cell-free body fluids using magnetic bead-based purification technology, compatible with manual and automated extraction systems.
- Viral Dtect Kit
Quantifiable outcome
- Detection of up to 20 targets from a single sample with OnePCR platform
- +4 more outcomes
Companies that use Genes2me (P) Limited
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Genes2me (P) Limited technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability1 record
Feature5 records
Genes2me (P) Limited partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- IlluminacoreIllumina mentioned as technology partner and brand collaboration. Company uses Illumina platforms and products including Single Cell 3' RNA Prep Kit. EZY AutoPrep referenced as compatible with Illumina workflows.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Genes2me (P) Limited competitors and assessment
Company assessmentDirect peers
- Mylab Discovery Solutions: Indian molecular diagnostics company that also scaled rapidly via COVID-19 RT-PCR kits (PathoDetect) and has expanded into routine molecular diagnostics, women's health, and animal health. Directly comparable to Genes2Me on geography, customer base, and IVD manufacturing model.
- Molbio Diagnostics: Indian molecular diagnostics company known for the Truenat point-of-care RT-PCR platform used widely for TB and infectious disease testing. Directly comparable as an Indian IVD manufacturer with proprietary POC molecular instruments and global distribution.
- MedGenome: India- and US-based genomics and molecular diagnostics company offering NGS-based genetic testing, oncology panels, and prenatal screening. Comparable as a peer offering NGS clinical assays and genetic testing services in overlapping disease areas.
Broad incumbents
- Roche Diagnostics: Global leader in IVD and molecular diagnostics with cobas systems and broad infectious disease, oncology, and genetics menus. Comparable as a molecular diagnostics incumbent whose installed base Genes2Me competes against in hospital labs.
- Thermo Fisher Scientific (Life Sciences / Clinical Diagnostics): Global IVD and life sciences tools company with Applied Biosystems PCR systems, NGS reagents, and clinical diagnostics offerings. Comparable as a broad incumbent supplying PCR instruments, kits, and reagents overlapping with Genes2Me's OnePCR/Rapi-Q/Rapi-X portfolio.
- Qiagen: Global molecular diagnostics and sample-preparation company with QIAcuity digital PCR, QIAstat-Dx syndromic testing, and nucleic acid extraction kits. Comparable as a broad incumbent with overlapping nucleic acid extraction and PCR product lines.
- Bio-Rad Laboratories: Established provider of CFX real-time PCR systems, digital PCR (QXDx), and IVD reagents. Comparable as a broad incumbent whose CFX96 platform is explicitly listed as compatible with Genes2Me's Viral Dtect kits.
- Hologic: Molecular diagnostics incumbent with the Panther system for women's health, infectious disease, and oncology testing. Comparable as a broad incumbent in molecular diagnostics with focus on automation and high-throughput workflows.
- Becton Dickinson (BD): Global medical devices and diagnostics company with BD MAX and FACS systems spanning molecular diagnostics and cell analysis. Comparable as a broad incumbent and former employer of Genes2Me's Chairman SK Gupta.
Emerging players
- 4baseCare: India-based precision oncology company offering NGS-based tumor profiling and liquid biopsy. Comparable as an emerging player in NGS oncology diagnostics with overlapping assay menu and target customer base in India.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genes2me (P) Limited social profiles
Digital presenceGenes2me (P) Limited compliance and trust
Trust signalCompliance3 records
Genes2me (P) Limited financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genes2me (P) Limited leadership team
Management profileNumber of profiles
Profiles10 records
Genes2me (P) Limited funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genes2me (P) Limited M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genes2me (P) Limited
What does Genes2me (P) Limited do?
Genes2Me develops, manufactures, and sells in vitro diagnostic (IVD) solutions including real-time PCR testing kits, NGS clinical assay panels, point-of-care molecular testing instruments, and automated nucleic acid extraction systems. The company also operates a genetic testing laboratory service offering personalized diagnostics for mother & child care, oncology, infectious diseases, rare diseases, and direct-to-consumer genetic profiling such as Genes2Fit, Genes2Health, Med4Me, and HealthyMe.
Is Genes2me (P) Limited a public or private company?
Genes2me (P) Limited is a private company. It is classified as family owned and is currently operating.
When was Genes2me (P) Limited founded?
Genes2me (P) Limited was founded in 2016. It employs 51 to 100 people.
Where is Genes2me (P) Limited based?
Genes2me (P) Limited is headquartered in Gurugram, India, in the Asia region.
How does Genes2me (P) Limited make money?
Three revenue lines are on record. IVD Kits and Instruments Sales are the primary driver. The others are genetic Testing Services and NGS Clinical Assays.
Who are Genes2me (P) Limited's main competitors?
Direct peers on record are Mylab Discovery Solutions, Molbio Diagnostics and MedGenome. Broad incumbents are Roche Diagnostics, Thermo Fisher Scientific (Life Sciences / Clinical Diagnostics), Qiagen, Bio-Rad Laboratories, Hologic and Becton Dickinson (BD). 4baseCare is listed as an emerging player.
Does Genes2me (P) Limited have an API?
No public API is recorded for Genes2me (P) Limited.
What industry is Genes2me (P) Limited in?
Genes2me (P) Limited's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument). Its NAICS code is 325413 and its SIC code is 2835.